Mattia Galli/LinkedIn
Nov 12, 2025, 05:16
Mattia Galli on The Choice in ASCVD: Aspirin or P2Y12 Inhibitor Monotherapy?
Mattia Galli, Assistant Professor at Sapienza University of Rome, Associate Editor of European Heart Journal, shared on LinkedIn:
”Should P2Y12 inhibitor be preferred over aspirin for long treatment in ASCVD patients?
All you need to know in this balanced, yet comprehensive State-of-the-Art review published in the European Heart Journal.”
Read the full article in EHJ.
Article: Aspirin or P2Y12 inhibitor monotherapy in atherosclerotic cardiovascular disease?
Authors: Mattia Galli, Jurrien ten Berg, Marco Valgimigli, Davide Capodanno, Felice Gragnano, Takeshi Kimura, Deepak L Bhatt, C Michael Gibson, Roxana Mehran, Dominick J Angiolillo
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 19, 2025, 18:03Andres Ricaurte Fajardo on a Strongyloides Stercoralis Hyperinfection with Thrombosis
-
Nov 19, 2025, 17:50Marilena Vrana Reflects on PPTA Europe’s Visits with Members and Stakeholders in 2025
-
Nov 19, 2025, 17:32Michael Makris Shares Insights from Global Forum Meeting of the WFH Meeting in Montreal
-
Nov 19, 2025, 17:14Yazan Abou Ismail Takes The Legacy Award from Qatar Foundation
-
Nov 19, 2025, 17:02Wolfgang Miesbach Shares Real-World Evidence on Eptacog Beta from Spain
-
Nov 19, 2025, 16:34Ishita Singh Reflects on Haematocon 2025: A Reminder of Her Commitment to The Journey
-
Nov 19, 2025, 16:23Mehdi Kashani: I’m Really Excited to Share Schistosite.com
-
Nov 19, 2025, 16:09A ”Meow-cyte” from Melaku Abay Muluneh or Why Microscopy Never Gets Old!
-
Nov 19, 2025, 15:56Cuilan Li on her Contribution to a Cutting-Edge Project in Polycythemia Vera